Total Payments
$157,106
2024 Payments
$61,825
Companies
27
Transactions
312
Medicare Patients
6,065
Medicare Billing
$4.5M
Payment Breakdown by Category
Other$87,764 (55.9%)
Consulting$37,630 (24.0%)
Food & Beverage$13,029 (8.3%)
Travel$11,624 (7.4%)
Research$6,950 (4.4%)
Education$110.03 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,364 | 14 | 41.0% |
| Consulting Fee | $37,630 | 11 | 24.0% |
| Honoraria | $23,400 | 9 | 14.9% |
| Food and Beverage | $13,029 | 236 | 8.3% |
| Travel and Lodging | $11,624 | 36 | 7.4% |
| Unspecified | $6,950 | 3 | 4.4% |
| Education | $110.03 | 3 | 0.1% |
Payments by Type
General
$150,156
309 transactions
Research
$6,950
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $43,289 | 52 | $0 (2024) |
| Alimera Sciences, Inc. | $35,807 | 54 | $0 (2024) |
| Biogen, Inc. | $33,107 | 30 | $0 (2024) |
| Genentech USA, Inc. | $20,133 | 43 | $0 (2024) |
| Allergan, Inc. | $7,109 | 21 | $0 (2021) |
| Genentech, Inc. | $5,889 | 5 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $5,262 | 13 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $1,615 | 2 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,155 | 9 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $544.37 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,825 | 109 | Regeneron Healthcare Solutions, Inc. ($40,206) |
| 2023 | $40,955 | 75 | Biogen, Inc. ($26,223) |
| 2022 | $17,631 | 44 | Alimera Sciences, Inc. ($7,591) |
| 2021 | $4,508 | 23 | Alimera Sciences, Inc. ($3,585) |
| 2020 | $9,011 | 14 | Alimera Sciences, Inc. ($8,900) |
| 2019 | $15,450 | 30 | Alimera Sciences, Inc. ($8,292) |
| 2018 | $452.09 | 8 | Allergan Inc. ($171.24) |
| 2017 | $7,275 | 9 | Alimera Sciences, Inc. ($6,950) |
All Payment Transactions
312 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/13/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/11/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $37.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | Harrow Eye, LLC | IHEEZO (Drug), TRIESENCE | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: OPTOMETRY | ||||||
| 11/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $67.96 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/20/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/19/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $225.99 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $28.58 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/18/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $341.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/15/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $212.37 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2024 | Harrow Eye, LLC | VEVYE (Drug) | Food and Beverage | In-kind items and services | $29.38 | General |
| Category: OPTOMETRY | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $29.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/08/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $142.37 | General |
| Category: Ophthalmology | ||||||
| 11/08/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $105.47 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Ophthalmology | ||||||
| 11/07/2024 | Oyster Point Pharma, Inc. | RYZUMVI (Drug), TYRVAYA | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Pharmacologically-induced mydriasis | ||||||
| 11/06/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 11/04/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: EYE CARE | ||||||
| 11/02/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,755.00 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $296.07 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $267.93 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $242.39 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALADIN | Alimera Sciences, Inc. | $6,950 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 785 | 1,153 | $533,460 | $188,256 |
| 2022 | 11 | 1,428 | 3,725 | $3.0M | $888,731 |
| 2021 | 16 | 1,902 | 6,974 | $6.0M | $1.8M |
| 2020 | 14 | 1,950 | 6,526 | $5.4M | $1.6M |
Total Patients
6,065
Total Services
18,378
Medicare Billing
$4.5M
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 29 | 150 | $187,500 | $102,471 | 54.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 227 | 267 | $53,400 | $30,584 | 57.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 53 | 145 | $110,250 | $15,271 | 13.9% |
| 92134 | Imaging of retina | Office | 2023 | 167 | 247 | $37,050 | $9,134 | 24.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 57 | 58 | $20,300 | $7,451 | 36.7% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 11 | 11 | $82,500 | $7,408 | 9.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 63 | $13,860 | $7,249 | 52.3% |
| 92250 | Photography of the retina | Office | 2023 | 159 | 180 | $24,120 | $6,033 | 25.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 27 | 32 | $4,480 | $2,655 | 59.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 103 | 852 | $1.6M | $616,987 | 39.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 31 | 517 | $364,485 | $117,748 | 32.3% |
| 67028 | Injection of drug into eye | Office | 2022 | 156 | 571 | $630,630 | $54,504 | 8.6% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 406 | 565 | $186,450 | $49,568 | 26.6% |
| 92134 | Imaging of retina | Office | 2022 | 399 | 830 | $178,035 | $25,273 | 14.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 101 | 135 | $26,730 | $8,711 | 32.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 48 | 48 | $21,120 | $4,985 | 23.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $13,640 | $3,226 | 23.7% |
| 92250 | Photography of the retina | Office | 2022 | 109 | 116 | $22,968 | $3,222 | 14.0% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 28 | 28 | $11,396 | $2,786 | 24.4% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 16 | 32 | $17,600 | $1,720 | 9.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 128 | 1,611 | $2.9M | $1.2M | 40.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 53 | 1,220 | $860,100 | $306,035 | 35.6% |
| 67028 | Injection of drug into eye | Office | 2021 | 193 | 1,081 | $1.2M | $110,479 | 9.1% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 503 | 929 | $306,570 | $90,204 | 29.4% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 496 | 1,429 | $306,521 | $47,328 | 15.4% |
About Deepika Malik
Deepika Malik is a Retina Specialist healthcare provider based in Woodbury, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2014. The National Provider Identifier (NPI) number assigned to this provider is 1134530306.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Deepika Malik has received a total of $157,106 in payments from pharmaceutical and medical device companies, with $61,825 received in 2024. These payments were reported across 312 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($64,364).
As a Medicare-enrolled provider, Malik has provided services to 6,065 Medicare beneficiaries, totaling 18,378 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Location Woodbury, NY
- Active Since 05/09/2014
- Last Updated 07/26/2024
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1134530306
Products in Payments
- EYLEA HD (Biological) $43,050
- ILUVIEN (Drug) $20,187
- Susvimo (Drug) $8,977
- Iluvien (Drug) $8,378
- Vabysmo (Drug) $7,752
- OZURDEX (Drug) $7,380
- ILUVIEN (Biological) $6,950
- XIPERE (Drug) $5,002
- VABYSMO (Drug) $2,016
- EYP-1901 (Drug) $1,615
- EYLEA (Biological) $1,347
- ACTHAR (Biological) $576.47
- Syfovre (Drug) $362.20
- BEOVU (Drug) $349.31
- MIEBO (Drug) $247.42
- SUSVIMO (Drug) $179.37
- NGENUITY (Device) $167.30
- YUTIQ (Drug) $164.35
- OXERVATE (Drug) $146.38
- VEVYE (Drug) $134.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.